Bacteriology and Inflammation in Bronchiectasis

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Bronchiectasis is a chronic disease arises from progressive airway inflammation and infection. It has been postulated that bacterial infection triggers intense airway inflammation leading to acute exacerbation of bronchiectasis. Antibiotics have been the most potent medications for the treatment of bronchiectasis, however, the sputum bacterial load and inflammatory indices at steady-state and exacerbation remain largely unknown. The investigation might shed light on the roles that antibiotics play in acute exacerbation of bronchiectasis and uncover the mechanisms on why a subgroup of individuals do not respond satisfactorily.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangzhou Institute of Respiratory Disease
• Treatments: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; beta-Lactamase Inhibitors; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• Patients of either sex and age between 18 and 70 years

Exclusion Criteria:

• Patient judged to have poor compliance

• Female patient who is lactating or pregnant

• Patients having concomitant severe systemic illnesses (i.e. coronary heart disease, cerebral stroke, uncontrolled hypertension, active gastric ulcer, malignant tumor, hepatic dysfunction, renal dysfunction)

• Miscellaneous conditions that would potentially influence efficacy assessment, as judged by the investigators

• Participation in another clinical trial within the preceding 3 months